POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Dosing POMALYST® (pomalidomide).
Tailor the POMALYST dosage to your patients’ needs.
4 dosage strengths are available for dose modifications1

Capsules shown are not actual size.
- The recommended dosage is 4 mg
- Additional strengths of 3 mg, 2 mg, and 1 mg are available for dose modification
Dose modifications may help patients stay on therapy.1

- *Permanently discontinue POMALYST if unable to tolerate 1 mg once daily.
- To initiate a new cycle of POMALYST, the platelet count must be at least 50,000 per mcL
In MM-003, thrombocytopenia of any grade was reported in 30% of patients treated with POMALYST + low-dose dex vs. 29% treated with high-dose dex.2†
- POMALYST + low-dose dex, n=300; high-dose dex, n=150.

- *Permanently discontinue POMALYST if unable to tolerate 1 mg once daily.
- Fever greater than or equal to 38.5 °C and ANC less than 1000 per mcL.
- To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL
In MM-003, neutropenia of any grade was reported in 51% of patients treated with POMALYST + low-dose dex vs. 21% treated with high-dose dex.2†
Permanently discontinue POMALYST for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reaction.
For other Grade 3 or 4 toxicities1:
- Hold treatment and restart treatment at 1 mg less than the previous dose when the
toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion
†POMALYST + low-dose dex, n=300; high-dose dex, n=150.
Selected Safety Information.
- Hematologic Toxicity: Neutropenia (46%) was the most frequently reported Grade 3 or 4 adverse reaction in patients taking POMALYST in clinical trials, followed by anemia and thrombocytopenia. Monitor complete blood counts weekly for the first 8 weeks and monthly thereafter. Patients may require dose interruption and/or modification.
ANC, absolute neutrophil count; CBC, complete blood count; dex, dexamethasone.
References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial. Lancet Oncol. 2013;14(11)1055-1066.